IL-26 and Systemic Lupus Erythematosus

Intérêt de l'IL-26 Comme Nouveau Marqueur Biologique du Lupus érythémateux systémique

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01889641

Enrollment

Registered

2013-06-28

Start date

2014-02-28

Completion date

2015-04-30

Last updated

2017-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnosis of Lupus According to ACR criteriaAgreement for the Blood Sampling

Brief summary

Treatment of multisystemic forms of lupus displays severe side effects and limited efficacy, underscoring the need to better dissection of the pathogenic mechanisms. Concordant with preliminary data, IL26 signaling could be impaired in systemic lupus. Moreover, IL 26 could be a marker of the disease activity and then a potential therapeutic target. In the present study, serum IL 26 level in lupus patients and control will be measured.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* diagnostic of Lupus according to ACR criteria ( four criteria are necessary) * age \> 18 years old

Exclusion criteria

* treatment by cyclophosphamide, rituximab, belimumab in the year before inclusion study

Design outcomes

Primary

Measure	Time frame
Assess serum IL-26 as a biological marker of SLE compared with sera from control subjects	2 years

Countries

France

Outcome results